Loading...
XNASIMNN
Market cap11mUSD
Dec 27, Last price  
0.79USD
1D
0.38%
1Q
-23.75%
Name

Imunon Inc

Chart & Performance

D1W1MN
XNAS:IMNN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
50.48%
Rev. gr., 5y
0.00%
Revenues
0k
-100.00%
2,506,22812,320,14111,250,81702,500,000002,000,0000500,000500,000500,000500,000500,000500,000500,000500,000500,000500,0000
Net income
-20m
L-45.64%
-13,985,048-8,685,319-7,584,23035,349,057-11,786,215-15,193,000-18,818,435-23,222,678-26,568,000-8,251,358-25,494,273-22,461,084-22,054,000-20,402,176-11,883,359-16,851,533-21,483,561-20,769,000-35,898,000-19,514,977
CFO
-19m
L-17.76%
-13,941,158-8,064,870-7,232,790-9,582,7852,281,263-930,331-13,367,389-22,742,437-22,329,593-9,471,517-21,353,020-20,830,563-18,379,364-16,642,076-7,041,686-20,258,982-15,618,676-16,223,603-23,131,376-19,022,148
Earnings
Mar 26, 2025

Profile

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
URL
https://imunon.com/
IPO date
Oct 27, 1993
Employees
31
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
500
0.00%
500
0.00%
Cost of revenue
21,750
26,154
22,210
Unusual Expense (Income)
NOPBT
(21,750)
(25,654)
(21,710)
NOPBT Margin
Operating Taxes
(1,280)
(1,567)
(1,384)
Tax Rate
NOPAT
(20,470)
(24,087)
(20,326)
Net income
(19,515)
-45.64%
(35,898)
72.84%
(20,769)
-3.33%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,781
(21,777)
52,689
BB yield
-45.22%
225.84%
Debt
Debt current
485
1,656
549
Long-term debt
2,764
4,842
6,865
Deferred revenue
Other long-term liabilities
5,396
Net debt
(12,446)
(30,879)
(48,084)
Cash flow
Cash from operating activities
(19,022)
(23,131)
(16,224)
CAPEX
(452)
(268)
(312)
Cash from investing activities
11,006
8,315
(30,123)
Cash from financing activities
(3,639)
6,723
54,768
FCF
(22,063)
(23,489)
(20,336)
Balance
Cash
15,696
32,877
49,498
Long term investments
4,500
6,000
Excess cash
15,696
37,352
55,473
Stockholders' equity
(388,028)
(368,567)
(332,720)
Invested Capital
403,040
404,162
400,546
ROIC
ROCE
EV
Common stock shares outstanding
9,045
7,143
362
Price
0.68
-49.63%
1.35
 
Market cap
6,151
-36.21%
9,643
 
EV
(6,295)
(21,236)
EBITDA
(21,030)
(24,922)
(21,007)
EV/EBITDA
0.30
0.85
Interest
4,573
557
Interest/NOPBT